Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of LY3484356 in Chinese Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

NCT05509790 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05509790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of LY3484356 in Chinese Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 9, 2022
Completion date
December 31, 2026
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms